Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SMTI 
Sanara Medtech Inc (SMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $49
1 Year Target Price $49
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.36% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 252.50M USD | Price to earnings Ratio - | 1Y Target Price 49 |
Price to earnings Ratio - | 1Y Target Price 49 | ||
Volume (30-day avg) 2 | Beta 1.33 | 52 Weeks Range 25.86 - 39.08 | Updated Date 06/30/2025 |
52 Weeks Range 25.86 - 39.08 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.48% | Operating Margin (TTM) -8.88% |
Management Effectiveness
Return on Assets (TTM) -4.72% | Return on Equity (TTM) -29.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 276535977 | Price to Sales(TTM) 2.76 |
Enterprise Value 276535977 | Price to Sales(TTM) 2.76 | ||
Enterprise Value to Revenue 3.02 | Enterprise Value to EBITDA -29.03 | Shares Outstanding 8887850 | Shares Floating 3593181 |
Shares Outstanding 8887850 | Shares Floating 3593181 | ||
Percent Insiders 66.47 | Percent Institutions 10.43 |
Analyst Ratings
Rating 2 | Target Price 49 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sanara Medtech Inc
Company Overview
History and Background
Sanara Medtech Inc. (formerly Wound Management Technologies) focuses on developing, marketing, and distributing wound and skin care products. Founded in 2008. They've grown through product development and strategic acquisitions.
Core Business Areas
- Wound and Skin Care: Develops, markets, and distributes wound and skin care products to physicians, hospitals, and patients.
Leadership and Structure
Ron Nixon is the current CEO. The company has a typical corporate structure with departments for R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- CellerateRX Surgical Activated Collagen: An enzymatic collagen powder indicated for partial and full-thickness wounds, pressure ulcers, surgical wounds, and diabetic foot ulcers. Revenue figures are not publicly available. Competitors include Integra LifeSciences and ACell, Inc. Market share is not publicly available.
- BIAKOSTM Antimicrobial Skin and Wound Cleanser: This product is a broad-spectrum antimicrobial solution that helps prevent infections in wounds and skin injuries. Revenue figures are not publicly available. Competitors include Mylan and other manufacturers of antimicrobial solutions. Market share is not publicly available.
Market Dynamics
Industry Overview
The wound care market is growing, driven by an aging population, increasing rates of diabetes and obesity, and advancements in wound care technologies.
Positioning
Sanara Medtech focuses on advanced wound care solutions, particularly collagen-based products. It aims to differentiate itself through innovative technology and clinical efficacy.
Total Addressable Market (TAM)
The global wound care market is estimated to be in the billions of dollars. Sanara Medtech is positioned to capture a portion of this TAM through its specialized products and targeted market approach.
Upturn SWOT Analysis
Strengths
- Proprietary collagen technology
- Focus on high-growth wound care market
- Strategic acquisitions to expand product portfolio
Weaknesses
- Smaller market capitalization compared to major competitors
- Limited financial resources for extensive marketing
- Dependence on key product lines
Opportunities
- Expansion into new geographic markets
- Development of new wound care products
- Strategic partnerships with larger healthcare companies
Threats
- Competition from larger, well-established companies
- Pricing pressures in the healthcare market
- Regulatory changes affecting wound care products
Competitors and Market Share
Key Competitors
- ITCI
- BSX
- ABMD
- HSDT
- MRKR
Competitive Landscape
Sanara Medtech competes with larger companies in the wound care market. Its advantages lie in its specialized products and technology, while its disadvantages include limited resources and market reach.
Major Acquisitions
Medical Products Laboratories, Inc.
- Year: 2018
- Acquisition Price (USD millions): 17.5
- Strategic Rationale: Expanded Sanara's product portfolio and manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Sanara Medtech has grown organically and through acquisitions. Historical growth has been variable. Growth will depend on the market conditions of the stock
Future Projections: Future growth projections will depend on the market conditions of the stock and analyst consensus will depend on recent news. Consult financial news outlets for projections.
Recent Initiatives: Recent initiatives could include new product launches, strategic acquisitions, and partnerships.
Summary
Sanara Medtech is a small cap company focused on the growing wound care market. Its proprietary collagen technology and strategic acquisitions position it for growth. However, it faces competition from larger players and needs to manage its resources effectively. Recent financial performance and pipeline advancements are key indicators of future potential. Strong pipeline growth is what the company needs to look out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanara Medtech Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2011-02-22 | Executive Chairman & CEO Mr. Ronald T. Nixon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 141 | Website https://sanaramedtech.com |
Full time employees 141 | Website https://sanaramedtech.com | ||
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.